Bendamustine and rituximab is effective and cost-effective in older cases with aggressive lymphomas?

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2694-2695

  Paydas, S ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; LARGE CELL LYMPHOMA; LETTER; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 82355172678     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr429     Document Type: Letter

References (3)

1. Weidmann E, Neumann A, Fauth F et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011; 22: 1839-1844.
2. Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 2010; 70: 1703-1718.
3. Peyrade F, Jardin F, Thieblemont C et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 460-468.